Spectinomycin

CHEMBL1167 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
332.4 g/mol
LogP
-3.1
Phase
4

Spectinomycin is an aminocyclitol antibiotic with a mechanism similar to aminoglycosides, inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit and interfering with mRNA translocation, used primarily as an alternative treatment for uncomplicated gonorrhea in patients who cannot tolerate cephalosporins or fluoroquinolones. Unlike aminoglycosides, it is not nephrotoxic or ototoxic at therapeutic doses. Its investigational use in stroke is based on potential neuroprotective properties unrelated to its antibiotic activity.

Khối lượng phân tử

332,3500 g/mol

LogP

-3,10

TPSA

130,00 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Delivers synthetic messenger RNA encoding a specific protein to host cells, where it is translated by ribosomes to produce the therapeutic protein without integrating into the host genome.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Delivers synthetic messenger RNA encoding a specific protein to host cells, where it is translated by ribosomes to produce the therapeutic protein without integrating into the host genome.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@@]3(O)C(=O)C[C@@H](C)O[C@H]3O[C@@H]2[C@H]1O

InChI

InChI=1S/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1

Molecular Formula

C14H24N2O7

HBD / HBA

5 / 9

Liên kết có thể quay

2

Nguyên tử nặng

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Spectinomycin is an aminocyclitol antibiotic with a mechanism similar to aminoglycosides, inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit and interfering with mRNA translocation, used primarily as an alternative treatment for uncomplicated gonorrhea in patients who cannot tolerate cephalosporins or fluoroquinolones. Unlike aminoglycosides, it is not nephrotoxic or ototoxic at therapeutic doses. Its investigational use in stroke is based on potential neuroprotective properties unrelated to its antibiotic activity.

Delivers synthetic messenger RNA encoding a specific protein to host cells, where it is translated by ribosomes to produce the therapeutic protein without integrating into the host genome.

Yes, Spectinomycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1167. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 15541. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.